Gary Riddle, MD
Family Medicine · Newburgh, INNPI 1942223839
Payments from drug & device makers
Across 420 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Pfizer$803
- AbbVie$662
- Novo Nordisk$648
- Lilly USA, LLC$584
- Boehringer Ingelheim$349
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,537100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 54 | $1,095 |
| Pfizer | 59 | $803 |
| AbbVie(2 entities) | 56 | $662 |
| Novo Nordisk | 39 | $648 |
| Lilly USA, LLC | 40 | $584 |
| Boehringer Ingelheim | 23 | $349 |
| Johnson & Johnson | 23 | $329 |
| Amgen | 17 | $252 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $251 |
| Novartis | 15 | $244 |
| Bayer | 11 | $183 |
| Abbott | 9 | $164 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $146 |
| Sumitomo Pharma America, Inc. | 6 | $110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $110 |
| GSK | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Ironshore Pharmaceuticals Inc. | 2 | $53 |
| Dexcom, Inc. | 3 | $48 |
| Corium, LLC | 3 | $45 |
| Shire North American Group Inc | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Nevro Corp. | 2 | $28 |
| Insulet Corporation | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Exact Sciences | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$6,548 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 127 | $91,067 |
| EliquisApixaban | 94 | $82,151 |
| JardianceEmpagliflozin | 86 | $68,576 |
| MounjaroTirzepatide | 33 | $44,692 |
| ZyprexaOlanzapine | 17 | $40,619 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $33,990 |
| XareltoRivaroxaban | 41 | $33,551 |
| TrulicityDulaglutide | 21 | $29,314 |
| OzempicSemaglutide | 30 | $28,073 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $26,597 |
| GemtesaVibegron | 32 | $15,106 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $11,485 |
| RybelsusSemaglutide | 11 | $9,186 |
| Potassium Chloride | 130 | $8,911 |
| EntrestoSacubitril/Valsartan | 13 | $8,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Zyprexa, Trulicity, Olanzapine | $584 | $116,70487 claims |
| AstraZenecaFarxiga | $1,095 | $91,067127 claims |
| PfizerEliquis | $803 | $82,15194 claims |
| Boehringer IngelheimJardiance | $349 | $68,57686 claims |
| Novo NordiskOzempic, Rybelsus | $648 | $37,25941 claims |
| Johnson & JohnsonXarelto | $329 | $33,55141 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $59 | $19,30933 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $110 | $15,10632 claims |
| NovartisEntresto | $244 | $8,22413 claims |
| MerckBelsomra | $11 | $4,50111 claims |
| AbbVieSynthroid | $662 | $2,52539 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $35 | $2,33413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Newburgh
- Renee Michelle GalenNewburgh$2.1M
- Ruston StoltzNewburgh$40K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.